Curia

Articles

Accelerated API Manufacturing by Combining Early-Stage and Late-Stage Process Development

Responding to the development of more novel therapies and fast-track designations means being equipped with the right processes and resources to support expedited approvals right from the beginning of process development.

Overcoming the Challenges of Drug Development in a CDMO setting 

Podcasts

You have your drug substance and need a parenteral formulation to administer it. This podcast will focus on the key factors to consider when choosing the ideal parenteral manufacturing CDMO partner. 

Outsourcing your Parenteral Manufacturing - Choosing the optimal CDMO

Outsourcing Your Parenteral Manufacturing, Choosing the Optimal CDMO

Antibodies and proteins are critical reagents with wide application in in vitro diagnostic developments, companion diagnostic and biomarker assays. Depending on final application, different quality standards may apply, from research use to full GMP production. Learn more about Curia’s GMP Production of antibodies & proteins for critical assays and diagnostic applications.

From development to GMP production in 100 days 

The clinical value of biologics for the treatment of many disease indications has been accompanied by phenomenal sales. By 2026, the global market for biologics is projected to increase to $537 billion. However, getting a promising drug candidate from formulation development to clinical phase production and commercial manufacturing can be daunting. Proper formulation development has a huge impact on whether a technology transfer to clinical phase fill-finish is successful. Learn more!